About OncoImmunity

Robust & reliable neoantigen prediction to empower the next generation cancer immunotherapies.

About OncoImmunity

OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy.

OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in a clinically actionable time-frame.

OncoImmunity AS is a privately held company founded in 2014 and is based in Oslo, Norway and Cambrigde, MA USA. The company is backed by capital financing from both life science and technology and artificial intelligence/software specialist investors, as well as a number of strong and highly experienced and renowned private investors.

Radforsk is the lead investor and has vast experience and a strong track record with developing early stage research-based companies in the immune-oncology sector. Radforsk works hands-on in directing OncoImmunity toward its success. StartupLab/Founders Fund, Grotmol Solutions, Geveran Trading Co. Ltd., MP Pensjon, Sundt and the Norwegian Cancer Society are among the other investors. The full list of the shareholders can be found here.

For investor relations and more information, please contact the OncoImmunity Chairman of the Board, Anders Tuv.

OncoImmunity has assembled a growing and experienced multidisciplinary team of bioinformaticians, software-engineers and data scientists with machine-learning expertise.

  • Richard Stratford Ph.D.
    CEO & Co-Founder
    Richard Stratford Ph.D.
  • Trevor Clancy Ph.D.
    CSO & Co-Founder
    Trevor Clancy Ph.D.
  • Jenny-Ann Malmberg Ph.D.
    Software Development Manager
    Jenny-Ann Malmberg Ph.D.
  • Hugues Fontenelle Ph.D.
    Bioinformatics Development Manager
    Hugues Fontenelle Ph.D.
  • Stig Jarle Pettersen
    Stig Jarle Pettersen

Dr. Stratford holds a PhD degree in immunology from Imperial College London. He has more than 10 years of experience in the vaccine industry and more than 15 years of commercial experience in biotechnology. In addtion Dr. Stratford has extensive experience in business development & patent management.

Dr. Clancy has a PhD degree in cancer bioinformatics from the University of Oslo. He has an immunological background developing computational immune-profiling methods, in several national and international cancer related projects. Dr. Clancy has more than 14 years experience in bioinformatics and 9 years of commercial experience in bioinformatics product development. He has an active scientific profile in applying immune informatics for biomarker discovery in cancer.

Dr. Malmberg has a PhD degree within fusion plasma physics from the Royal Institute of Technology (KTH) in Sweden. Dr. Malmberg has 20 years of experience in commercial software development including development and regulatory experience for CE IVD medical devices in the Healthtech industry.

Dr. Fontenelle has a PhD in Biomedical Engineering from the University of Patras in Greece. Dr. Fontenelle has 15 years experience in biomedical engineering, software development and bioinformatics - with expertise in the development of clinical grade pipelines to analyze NGS data in the field of medical genetics.

Mr Pettersen is a graduate of the Norwegian School of Economics & Business Administration. He is an executive member of the board in Affitech AS. Mr. Pettersen is also on the board of Actigen Ltd. Previously Mr. Pettersen held the position of Chief Financial Officer of Xellia Pharmaceuticals AS and Chief Financial Officer for Cermaq ASA.

A bionformatics company governed by seasoned biotechnology and software directors.

  • Anders Tuv
    Chairman of the Board
    Anders Tuv
  • Tom A. Thorsen
    Board Member
    Tom A. Thorsen
  • Svenn Widerberg
    Board Member
    Svenn Widerberg

Mr. Tuv is currently Investment Director at early stage life science investment company Radforsk with a focus on immunotherapies and precision medicines. He is an experienced investment and business development professional with broad experience from the health care and biotech industry covering C-level positions, strategy and business development, research collaborations, licensing deals, M&As and IPOs. He has extensive experience with establishing and developing early stage biotech companies, as well as fundraising and private placements as an investor.

In addition to his position as Chairman of the Board of OncoImmunity, Mr. Tuv Non-executive Director Zelluna Immunotherapy, Non-executive Director Vaccibody, Non-executive Director Nextera, Non-executive Director Oslo Cancer Cluster Incubator, and member of the Nomination Committee of Targovax ASA.

Mr Thorsen is the CEO at Algot Invest AS, and an investor with extensive board level experience. Mr. Thorsen has over twenty years experience in Star Holding AS at both the management and board level, and was appointed chairman of the board in 2012 leading to the succesful sale of the company. Mr Thorsen has been a private investor since 1995, and has held numerous board and chairman positions in several successful portfolio companies. He was a board member in Tantan, which started in 2014, and successfuly sold to Momo (NASDAQ, China's leading mobile networking platform) in February 2018 for USD 735M.

Mr Widerberg is a serial entrepreneur and Master in Business with experience from senior positions in international communication and software companies.

Most recently Svenn founded KSD Software, and as the CEO built the company from scratch to a leading European software provider of electronic customs and security filings. KSD Software was a driver for a transformative change in the value chain of European freight/forwarding business with over 1300 clients including Adidas, IKEA and DHL. With eight offices located in Scandinavia and BeNeLux, KSD Software covered 27 countries in Europe and declared around 20% of all goods into Europe.

Svenn successfully exited with a sale of KSD Software to Descartes in 2013.

A development environment deeply immersed in the combined scientific fields of bioinformatics, biotechnology, onco-immunology and data science

  • Professor Eivind Hovig
    Bioinformatics Advisor
    Professor Eivind Hovig
  • Professor Arnoldo Frigessi
    Statistics Advisor
    Professor Arnoldo Frigessi
  • Professor Gustav Gaudernack
    Cancer Immunotherapy
    Professor Gustav Gaudernack
  • Øyvind Grotmol
    Machine Learning Advisor
    Øyvind Grotmol

The research activity of Professor Hovig centers on cancer and bioinformatics. Professor Hovig currently leads both a bioinformatics research team at the Department of informatics, University of Oslo, and a systems biology of melanoma team at the Oslo University Hospital, and he has published more than 160 international peer-review papers. He serves in a number of community roles, including being the scientific lead at the Oslo University Hospital bioinformatics core facility and is tightly integrated with the Norwegian national bioinformatics & genomics efforts, in addition to the bioinformatics activities at the Norwegian Cancer Genome Consortium. Professor Hovig is part of the management group of Elixir Norway. He has also co-founded several Norwegian biotech companies.

Professor Frigessi di Rattalma is an Italian statistician based in Norway, where he is a professor at the Department of Biostatistics with the Institute of Basic Medical Research at the University of Oslo. Professor Frigessi is director of the Norwegian Centre of Excellence for Research-Based Innovation "Big Insight - Statistics for the Knowledge Economy", and Director of the Oslo Centre for Biostatistics and Epidemiology, University of Oslo. He is an Adjunct Research Scientist at the Norwegian Computing Centre and actively developing innovative stochastic models carefully representing fundamental principle and mechanisms of complex systems. Frigessi's research work has been geared towards Bayesian statistics, on both the methodogical and applied side. Frigessi is a fellow of the Norwegian Academy of Technological Sciences, and was elected member of the Norwegian Academy of Science and Letters in 2008.

Professor Gaudernack was the head of Unit for Cancer Immunotherapy at the Norwegian Radium Hospital from 1995 to 2010, where he initiated an extensive cancer immunotherapy program, including more than 20 clinical studies of cancer vaccines targeting key factors in carcinogenesis and cellular therapy of cancer. His group pioneered vaccines targeting neoantigens (mutant K- and N-ras), starting as early as 1993. Professor Gaudernack has published 200 international peer-reviewed papers and is the co-founder of several cancer immunotherapy companies. He is presently CSO of Ultimovacs AS. He has more than 50 patents and 15 licenses of monoclonal antibodies, cancer vaccines and cancer diagnostics.

Mr Grotmol is the founder, CEO & CTO of Exabel. He has 12 years of experience as a successful tech and AI entrepreneur. He was Director of Research & Innovation at Medallia and VP at Energy Micro, and did extensive AI research as Senior Scientist at Brain Corp.

Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK